IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

Stifel raised the firm’s price target on IGM Biosciences (IGMS) to $27 from $25 and keeps a Buy rating on the shares. The firm believes management’s ability to provide a preliminary mid-FY25 update ...

Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that could adversely impact its business and financial ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price objective increased by Royal Bank of Canada from $17.00 to $20.00 in a research note published on Friday morning, Benzinga reports.

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

The company’s 50 day moving average is $14.23 and its 200-day moving average is $10.74. IGM Biosciences has a 12 month low of $3.81 and a 12 month high of $22.50. The firm has a market cap of $1 ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and ...

IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on developing treatments for autoimmune diseases, has recently undergone a significant strategic shift that has caught the ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.